Thus, an effect of FTI in down regulating mTOR signal ing might account for its antiproliferative action in malignancies in which TORC1/S6K activation plays an important role. That this is the case is also suggested by the finding that the clinically relevant FTI, SCH66336, inhibits mTOR signaling. It has been sug gested that this might be due to defective RheB farnesy lation upon FTI treatment. The fact, however, that the yeast RheB homologue does not appear to act upstream of TOR1 suggests that the transcriptional deregulation of TOR downstream effectors as seen in this study does not depend on poor prenylation of a yeast RheB like protein. Interestingly, many genes transcriptionally deregulated in FTase deficient cells belong to the category of tumor suppressors.
These observations support the view that FTI treatment might result in different responses depending on the role that PTEN or the DLC 1 tumor suppressor has in a given cancer pathology. Finally, it is noteworthy that the up regulation of the multidrug resistance machinery occurs solely in FTI treated cells. Due to the high number of MDR and ABC transporter genes in mammalian cells, as well as uncertainty as to the direct orthologues of the yeast Pdr5 and Pdr1 genes, it was not possible to directly reci procate this finding in mammalian cells. However, sup porting our array and image analyses, a marked up regulation of ATP11a but also decreased expression of the ABC transporter ABCA1 has been associated with SCH66336 resistance in murine lymphoblasts.
Others have reported that Tipifarnib, another FTI used in clinical trials, has an inhibitory effect on MDR trans porter activity via an as yet unknown mechanism. Curiously, however, FTI 277 reduces endogenous expression of MDR1 in the human colorectal cancer cells HCT 15 and SW620 14. All together, the yeast and mammalian data suggest that FTI inhibitors impact on the multidrug resistance response at different levels and different members of the ABC transporter superfamily are involved. Thus, the MDR response has to be carefully evaluated case by case upon FTI treatment. In conclusion, this study shows that FTase inhibition activates, in yeast and in mammals, a well defined tran scriptional response. We propose that defects in FTase activity are per se a cellular stress, normally monitored by Ras/PKA and TOR/Sch9/S6K1 responding genes.
Further more, this study shows that even suboptimal concentra tions of FTI drugs can boost the detoxification pathways leading to MDR up regulation and thus to FTI resistance. Methods Yeast strains, drug compounds, plasmid constructs, media and growth conditions for yeast cells Strains, plasmids and oligonucleotides are listed AV-951 in Table 1, Table 2 and Table 3, respectively. BY4741 and YDL090C ram1 strains were purchased from EUROSCARF, the K699, W303 and ras2 strains were a gift from Prof. Kim Nasmyth.